1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1635
  6. Examiner Gibbs

Examiner Gibbs Terra C

1635-GIBBS-TERRA-C

Employment Information

Art Unit:1635 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
435 — Chemistry: molecular biology and microbiology
424 — Drug, bio-affecting and body treating compositions
324 — Electricity: measuring and testing
604 — Surgery
370 — Multiplex communications
414 — Material or article handling
800 — Multicellular living organisms and unmodified parts thereof and related processes
Phone:(571) 272-0758
Email:terra.gibbs@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:24 years
Grade:GS-14

Grant Rate and Difficulty Ranking

77
3-Year Grant rate: 55% over 390 cases
Difficulty: Harder
Difficulty Percentile: 77th

With Examiner Gibbs, you have a 55% chance of getting an issued patent by 3 years after the first office action. Examiner Gibbs is a harder examiner and in the 77th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Gibbs, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1635

Examiner Gibbs's grant rate is higher than that of Art Unit 1635 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Gibbs 1.7
Art Unit 1635 1.6

Interview Benefit

Grant Rate without Interview

Examiner Gibbs has granted 186 of 346 cases without any applicant-requested interviews for a grant rate of 54%.

Grant Rate with Interview

Examiner Gibbs has granted 27 of 44 cases with at least one applicant-requested interview for a grant rate of 61%.

Interview Benefit

With Examiner Gibbs, conducting an interview increases your chance of getting a patent granted by 13%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
19258035 Oligonucleotides For Inducing Paternal Ube3a Expression Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18493610 Compositions For Modulating Ataxin 2 Expression Patented View
18181057 Conjugates And Preparation And Use Thereof Abandoned View
18529152 Complement Component C5 Irna Compositions And Methods Of Use Thereof Patented View
17295208 Liver-Specific Regulatory Nucleic Acid Sequences Patented View
17297193 Double Stranded Oligonucleotide Construct Comprising Androgen Receptor Specific Sequence, And Composition For Preventing Hair Loss And Promoting Hair Growth Comprising Same Patented View
17782797 Inhibitors Of Kdm5a For Use In Treatment Of Idiopathic Inflammatory Myopathies Abandoned View
18491513 Oligonucleotides For Inducing Paternal Ube3a Expression Patented View
17778366 Ataxin3 (Atxn3) Rnai Agent Compositions And Methods Of Use Thereof Patented View
18598943 Sirna Structures For High Activity And Reduced Off Target Abandoned View
18433225 Method For Quantifying An Amount Of Capped Messenger Rna Patented View
17915985 Targeted Degradation Of The Oncogenic Microrna 17-92 Cluster By Structure-Targeting Ligands Abandoned View
16908517 Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Reduction Abandoned View
17907741 Alpha-2a Adrenergic Receptor (Adra2a) Irna Agent Compositions And Methods Of Use Thereof Patented View
17900921 Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof Abandoned View
17626775 Variant Reverse Transcriptase Exhibiting Excellent Stability Abandoned View
18080954 Defibrotide For The Prevention And Treatment Of Cytokine Release Syndrome And Neurotoxicity Associated With Immunodepletion Patented View
18606312 Control Of Insect Infestation Patented View
18465077 Loop-Mediated Synthetic Riboregulators Patented View
17929950 Compositions And Methods For Inhibiting Asah1 Gene Expression Abandoned View
17802905 Fidgetin-Like 2 As A Target To Enhance Skin Graft Healing Abandoned View
18633108 Hippo And Dystrophin Complex Signaling In Cardiomyocyte Renewal Patented View
18794874 Enzymatic Rna Capping Method Patented View
17786344 Template-Free Enzymatic Polynucleotide Synthesis Using Dismutationless Terminal Deoxynucleotidyl Transferase Variants Abandoned View
17254194 Compositions And Methods For Ameliorating Tissue Injury, Enhancing Liver Regeneration And Stem Cell Therapies Abandoned View
17631087 Subcutaneous Delivery Of Multimeric Oligonucleotides With Enhanced Bioactivity Abandoned View
17696510 Inhibiting Ape2 Expression In A Subject Treated With A Drug Agent That Causes Increased Ape2 Expression Patented View
17586850 Pcsk9 Irna Compositions And Methods Of Use Thereof Patented View
17776399 Antisense Oligonucleotide Sequences For Silencing The Human L1-Met Transcript In Tumors Patented View
16486887 Aptamer As Biomarkers Abandoned View
17286655 Modified Nucleic Acid Having Improved Treatment Efficacy, And Anticancer Pharmaceutical Composition Containing Same Patented View
17777792 Antisense Oligonucleotides And Thier Use For The Treatment Of Cancer Abandoned View
18368620 Rna Interference Mediated Inhibition Of Catenin (Cadherin-Associated Protein), Beta 1 (Ctnnb1) Gene Expression Using Short Interfering Nucleic Acid (Sina) Abandoned View
18218638 Complement Component C5 Irna Compositions And Methods Of Use Thereof For Treating Paroxysmal Nocturnal Hemoglobinuria (Pnh) Abandoned View
17865156 Topical Composition Comprising Retinol And Pdrn And Use Of Same Patented View
18634158 Use Of Pi3kc2b Inhibitors For The Preservation Of Vascular Endothelial Cell Barrier Integrity Abandoned View
17554476 Microrna Assay For Detection And Management Of Pancreatic Cancer Precursors Patented View
18487302 Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof Patented View
17615413 Oligonucleotide Therapy For Wolman Disease And Cholesteryl Ester Storage Disease Abandoned View
17001236 Enzymatic Rna Capping Method Patented View
17714717 Materials And Methods Of Treating Mhc-1-Opathy Risk Haplotypes Patented View
16519607 Efficient Protein Expression In Vivo Using Modified Rna (Mod-Rna) Patented View
18524302 Methods For Treatment Of Polycystic Kidney Disease Abandoned View
17766153 Chemical Modifications Of Small Interfering Rna With Minimal Fluorine Content Abandoned View
17317688 Method And Means To Deliver Mirna To Target Cells Abandoned View
17494751 Stabilized Polyribonucleotide Coding For An Elastic Fibrous Protein Patented View
18218155 Factor Xii (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (Klkb1), And Kininogen 1 (Kng1) Irna Compositions And Methods Of Use Thereof Patented View
18886396 Apoptotic Cell Mimic Patented View
18071424 Methods And Compositions For Inhibiting Expression Of Ldha Abandoned View
17893742 In Vitro Transcription Technologies Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.